{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:23:46Z","timestamp":1787765026674,"version":"build-2784847793"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T00:00:00Z","timestamp":1552867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009480","name":"Stichting Vrienden van het Sophia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.ebiom.2019.03.048","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T10:37:28Z","timestamp":1553510248000},"page":"553-561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["A genetic modifier of symptom onset in Pompe disease"],"prefix":"10.1016","volume":"43","author":[{"given":"Atze J.","family":"Bergsma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn L.M.","family":"in 't Groen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.A.","family":"van den Dorpel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannerieke J.M.P.","family":"van den Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine A.M.E.","family":"van der Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Schoser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Toscano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olimpia","family":"Musumeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Bembi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Dardis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Morrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albina","family":"Tummolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ans T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7042-2482","authenticated-orcid":false,"given":"W.W.M. Pim","family":"Pijnappel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9646","key":"10.1016\/j.ebiom.2019.03.048_bb0005","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ebiom.2019.03.048_bb0010","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1756285609103324","article-title":"Progress in enzyme replacement therapy in glycogen storage disease type II","volume":"2","author":"Angelini","year":"2009","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"10.1016\/j.ebiom.2019.03.048_bb0015","doi-asserted-by":"crossref","first-page":"10898","DOI":"10.1038\/s41598-018-29170-7","article-title":"Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study","volume":"8","author":"Figueroa-Bonaparte","year":"2018","journal-title":"Sci Rep"},{"issue":"23","key":"10.1016\/j.ebiom.2019.03.048_bb0020","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","article-title":"Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study","volume":"89","author":"Kuperus","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ebiom.2019.03.048_bb0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00415-017-8686-6","article-title":"Pompe disease in Austria: clinical, genetic and epidemiological aspects","volume":"265","author":"Loscher","year":"2018","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.ebiom.2019.03.048_bb0030","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/humu.20374","article-title":"Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II","volume":"27","author":"Montalvo","year":"2006","journal-title":"Hum Mutat"},{"issue":"4","key":"10.1016\/j.ebiom.2019.03.048_bb0035","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2017.10.008","article-title":"Sensitivity of whole exome sequencing in detecting infantile- and late-onset Pompe disease","volume":"122","author":"Mori","year":"2017","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.ebiom.2019.03.048_bb0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ymgme.2010.09.002","article-title":"Body composition analysis in late-onset Pompe disease","volume":"102","author":"Papadimas","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"5","key":"10.1016\/j.ebiom.2019.03.048_bb0045","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10545-012-9451-8","article-title":"36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy","volume":"35","author":"Regnery","year":"2012","journal-title":"J Inherit Metab Dis"},{"issue":"12","key":"10.1016\/j.ebiom.2019.03.048_bb0050","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1007\/s00415-018-9065-7","article-title":"36-months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe registry","volume":"265","author":"Scheidegger","year":"2018","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.ebiom.2019.03.048_bb0055","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s10545-018-0243-7","article-title":"Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study","volume":"41","author":"Semplicini","year":"2018","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"10.1016\/j.ebiom.2019.03.048_bb0060","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s10545-018-0166-3","article-title":"Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy","volume":"41","author":"van der Meijden","year":"2018","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"10.1016\/j.ebiom.2019.03.048_bb0065","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.pjnns.2018.05.002","article-title":"Enzymatic replacement therapy in patients with late-onset Pompe disease - 6-year follow up","volume":"52","author":"Witkowski","year":"2018","journal-title":"Neurol Neurochir Pol"},{"key":"10.1016\/j.ebiom.2019.03.048_bb0070","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1750-1172-7-35","article-title":"A cross-sectional single-Centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations","volume":"7","author":"Herzog","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"10.1016\/j.ebiom.2019.03.048_bb0075","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/hmg\/3.7.1081","article-title":"A de novo 13 nt deletion, a newly identified C647W missense mutation and a deletion of exon 18 in infantile onset glycogen storage disease type II (GSDII)","volume":"3","author":"Huie","year":"1994","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.ebiom.2019.03.048_bb0080","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1212\/01.wnl.0000252798.25690.76","article-title":"Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype","volume":"68","author":"Kroos","year":"2007","journal-title":"Neurology."},{"issue":"8\u20139","key":"10.1016\/j.ebiom.2019.03.048_bb0085","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.neurol.2013.07.002","article-title":"Baseline characteristics of a cohort of 126 patients with adult Pompe disease","volume":"169","author":"Laforet","year":"2013","journal-title":"Rev Neurol (Paris)"},{"issue":"9\u201310","key":"10.1016\/j.ebiom.2019.03.048_bb0090","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.nmd.2007.06.002","article-title":"Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients","volume":"17","author":"Muller-Felber","year":"2007","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"10.1016\/j.ebiom.2019.03.048_bb0095","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.nmd.2015.07.002","article-title":"Homozygosity for the common GAA gene splice site mutation c.-32-13T>G in Pompe disease is associated with the classical adult phenotypical spectrum","volume":"25","author":"Musumeci","year":"2015","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1016\/j.ebiom.2019.03.048_bb0100","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00401-005-1026-4","article-title":"Delayed or late-onset type II glycogenosis with globular inclusions","volume":"110","author":"Sharma","year":"2005","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1016\/j.ebiom.2019.03.048_bb0105","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J Neurol"},{"issue":"Suppl. 1","key":"10.1016\/j.ebiom.2019.03.048_bb0110","first-page":"S4","article-title":"Pompe disease newborn screening working G","volume":"140","author":"Bodamer","year":"2017","journal-title":"Newborn Screen Pompe Dis Pediatr"},{"issue":"6","key":"10.1016\/j.ebiom.2019.03.048_bb0115","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/ene.13285","article-title":"European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience","volume":"24","author":"van der Ploeg","year":"2017","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1016\/j.ebiom.2019.03.048_bb0120","article-title":"Punch biopsy of the skin","volume":"65","author":"Zuber","year":"2002","journal-title":"Am Fam Physician"},{"issue":"1","key":"10.1016\/j.ebiom.2019.03.048_bb0125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/humu.22705","article-title":"Identification and characterization of aberrant GAA pre-mRNA splicing in pompe disease using a generic approach","volume":"36","author":"Bergsma","year":"2015","journal-title":"Hum Mutat"},{"issue":"3","key":"10.1016\/j.ebiom.2019.03.048_bb0130","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s10545-009-1082-3","article-title":"Enzyme analysis for Pompe disease in leukocytes; superior results with natural substrate compared with artificial substrates","volume":"32","author":"van Diggelen","year":"2009","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"10.1016\/j.ebiom.2019.03.048_bb0135","first-page":"887","article-title":"Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II","volume":"56","author":"Boerkoel","year":"1995","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.ebiom.2019.03.048_bb0140","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/nar\/gkt987","article-title":"Functional characterization of the common c.-32-13T>G mutation of GAA gene: identification of potential therapeutic agents","volume":"42","author":"Dardis","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ebiom.2019.03.048_bb0145","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.omtn.2017.03.002","article-title":"GAA deficiency in Pompe disease is alleviated by exon inclusion in iPSC-derived skeletal muscle cells","volume":"7","author":"van der Wal","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.ebiom.2019.03.048_bb0150","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.omtn.2017.03.001","article-title":"Antisense oligonucleotides promote exon inclusion and correct the common c.-32-13T>G GAA splicing variant in Pompe disease","volume":"7","author":"van der Wal","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"issue":"6","key":"10.1016\/j.ebiom.2019.03.048_bb0155","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10545-018-0159-2","article-title":"Newborn screening for Pompe disease: impact on families","volume":"41","author":"Pruniski","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ebiom.2019.03.048_bb0160","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/1750-1172-8-182","article-title":"Phenotypical variation within 22 families with Pompe disease","volume":"8","author":"Wens","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ebiom.2019.03.048_bb0165","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13023-014-0102-z","article-title":"Genotype-phenotype correlation in Pompe disease, a step forward","volume":"9","author":"De Filippi","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ebiom.2019.03.048_bb0170","first-page":"48","article-title":"The influence of a polymorphism in the gene encoding angiotensin converting enzyme (ACE) on treatment outcomes in late-onset Pompe patients receiving alglucosidase alfa","volume":"8","author":"Baek","year":"2016","journal-title":"Mol Genet Metab Rep"},{"issue":"12","key":"10.1016\/j.ebiom.2019.03.048_bb0175","doi-asserted-by":"crossref","first-page":"e0208854","DOI":"10.1371\/journal.pone.0208854","article-title":"The ACE I\/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease","volume":"13","author":"Kuperus","year":"2018","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ebiom.2019.03.048_bb0180","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.ymthe.2017.05.019","article-title":"Glycogen reduction in myotubes of late-onset Pompe disease patients using antisense technology","volume":"25","author":"Goina","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2019.03.048_bb0185","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/bs.ircmb.2017.07.008","article-title":"Alternative splicing in genetic diseases: improved diagnosis and novel treatment options","volume":"335","author":"Bergsma","year":"2018","journal-title":"Int Rev Cell Mol Biol"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396419301938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396419301938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:53:23Z","timestamp":1762455203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396419301938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":37,"alternative-id":["S2352396419301938"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.03.048","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A genetic modifier of symptom onset in Pompe disease","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.03.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}